Academic Department of Trauma and Orthopaedics, University of Leeds, UK.
Injury. 2009 Dec;40 Suppl 3:S21-6. doi: 10.1016/S0020-1383(09)70007-5.
The central role of bone morphogenetic proteins (BMPs) in the remodelling process of the human skeleton has been identified in numerous experimental and clinical studies. BMPs appear to be key agents in the osteoblastic differentiation of mesenchymal stem cells, and more recent evidence implicates them with the cells of the osteoclastic lineage. BMP-2, BMP-4, BMP-6 and BMP-7 have been studied in the context of osteoporosis and have been associated with its pathophysiological pathways. The theoretical advantages of local or systemic treatment of osteoporotic fractures with BMPs include the potential of inducing a rapid increase in bone strength locally at the fractured area and systemically in the entire skeleton, as well as accelerating the bone-healing period. Animal models of osteoporotic fractures suggested that the induction of new bone by local or systemic use of BMP-7 should be investigated as potential bone augmentation therapy to improve bone quality in symptomatic spinal osteoporosis. As our knowledge expands, new innovations may provide clinicians with advanced biologically-based therapies for the successful treatment of osteoporotic fractures.
在大量的实验和临床研究中已经确定了骨形态发生蛋白（BMPs）在人类骨骼重塑过程中的核心作用。BMPs 似乎是间充质干细胞成骨分化的关键因子，最近的证据表明它们与破骨细胞谱系的细胞有关。BMP-2、BMP-4、BMP-6 和 BMP-7 已在骨质疏松症的背景下进行了研究，并与骨质疏松症的病理生理途径有关。用 BMP 局部或全身治疗骨质疏松性骨折的理论优势包括在骨折部位局部和整个骨骼系统中快速增加骨强度的潜力，以及加速骨折愈合期。骨质疏松性骨折的动物模型表明，应研究局部或全身使用 BMP-7 诱导新骨形成作为潜在的骨增强治疗，以改善有症状的脊柱骨质疏松症中的骨质量。随着我们知识的扩展，新的创新可能为临床医生提供先进的基于生物学的治疗方法，以成功治疗骨质疏松性骨折。
